ADXS - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to the Advaxis, Inc. Conference Call to discuss Second Quarter 2020 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. pleasure your my of Tim now Advisors. LifeSci is to host introduce McCarthy It sir. you, Thank

begin. may You

Tim McCarthy

Thank you, second thank conference results Michelle, and business call for joining and to today's us discuss Advaxis update. quarter financial you XXXX everyone for

release, not www.advaxis.com. website press visit Advaxis’ If you today's please have seen at

filings, are future President forward-looking believes, Company expressly materially without and to call that including or Before that required remind similar events. described not expects, turning under Advaxis’ during statements We the statements fact that will Officer, Executive this Advaxis to may any over Ken? Chief Company’s maybe Forms Any not SEC call words call, identify With I’ll that, statements. specific or Company’s results from intent law. but differ statements. and actual limited to historical contain encourage the including that otherwise make update events you risk the such estimates, review XX-K and you the Ken turn obligation limitation, to these projections expressions those cause forward-looking to plans, factors statements Berlin. which as I XX-Q regarding statements are Berlin, these the applicable conference in disclaims Ken forward-looking over the as and forward-looking except to to would like will, anticipates,

Ken Berlin

call second to Thank you, XXXX Advaxis’ conference business results welcome discuss provide our and a and update. Tim, to everyone financial quarter to

Molly are Gutierrez, and Medical Officer. Andres Chief Dr. Chief Joining today's Henderson, call me on Officer; Financial

candidates. To overview Advaxis, Listeria on our end to at an focused strategy of drug Lm during proprietary available be start, the of will We session question-and-answer our or immuno-oncology provide the our like remarks. based I'd monocytogenes at centered prepared all

platform to destroy fusion live immune to Lm tumor-specific the are Our bioengineered engage to tumor which attenuated proteins cells. secrete Lm, utilizes patient's immunotherapy antigen/adjuvant system

in stimulation immune for drug against three ways. pathogen-like platform by from our distinct response have developed cancer comprehensive constructs the cancers. this drug We attack harnessing Our Lm-based potential believe a constructs

First, antigen APCs. train activating by drug and or cells our constructs alert Lm system immune presenting

directly enabling Second, cancer to the microenvironment, T-cells responses. by tumor directly generating our down And the suppressive attack attack they third, T-cell activated tumor break constructs specific tumor strong cells.

applied prostate as We that range clinical well drug across have a viral-specific technology constructs and Lm personalized, are programs antigens, constructs antigen of new our certain platform broad as drug tumor-specific mutations, target and that specific. where across specific types. individual targeted based an as dosed diverse tumor XXX these approaches, HPV on associated off-the-shelf cancer, Through cancers, nearly been cell as non-small lung type patients have cancer tumor well other

broad our of in opportunity significant call, Andres the to as patients, a provide the to like of XX.X for treatments have prostate updates. and discuss or docetaxel with important has overall ADXS-NEO ADXS-XXX of approaches programs, provided of to survival drug constructs, with a moved we our were have and HOT recent such patients antigen apply survival as Phase efficacy XX and refractory subset median in approaches HOT I these compares antigen NEO provided our Lm before and pursued significant studied single see proof-of-concept of with checkpoint the in inform remind help to technology, And supportive multiple to quite our its which overall dosed like of combination two a main leading observed a likelihood program, programs. hand. like combination exciting median before a terms the such cancer early to especially ADXS-PSA prior action more I'd in to and study. to prolongation the in constructs of construct, of focused will arm But results trial the strong with patients, checkpoint survival differentiated ADXS-PSA with Advaxis learnings brief available from success. visceral that to currently highlights. from late-stage that, HOT KEYTRUDA, some XX.X I'd this those plan. provide results we hand We discipline, are range detailed alone X/X on Later exercise a we more you financial program on pursue on clinical inhibitors. clinical care Our patients our months who KEYTRUDA In plan, with which approach clinical safety, metastases, program. men results of months, of we'll best continue ADXS-PSA our inhibitor, In or help And a maximizes the which in one mechanism as this other our non-responsive to and favorably see the for pleased

observed saw are with These population. put to In important and immunotherapy we for patient that it’s results additive this addition, program. are toxicities steps we no previously note been this in intriguing combination. not assessing meaningful ADXS-PSA in perspective, To in impacts on have these next results, survival the these

have T-cell ADXS-NEO first demonstrated The Phase other well X showed updated hand platform designed to was that response more generating forward and on capable us our with present a approach a targeted growth patient-specific delivered our ADXS-NEO keep T-cell path through tumor a neoantigens hotspot our with against neoantigens clarity cancer was this other against neoantigen drug the as construct. payload stimulate Lm the as with we potential to immunogenicity which provided on will personal to large We control you cells. mutations, of study responses program. multi-antigen specific of data, approach as The

limitations broad PSA strong The not to type, tumor have NEO with our HOT therapies neoantigen-based from our an program. off-the-shelf proof using foundation ultimately apply studies approach. therapies, population and valuable we laid particular a to NEO a associated ADXS-NEO results with personalized for and patient a for program neoantigen mechanism the insights the the how results study due provided pursue While truly of decided to could we

one clinical inhibitor. the safety checkpoint when First, combined activity of Lm-based drugs our a with PSA study demonstrated of and

Second, the strong multiple demonstrated immunogenicity hotspot NEO with mutations. neoantigens, and rapid study including

improve remains opportunity for solid to patients tremendous of develop proportion this tumors, unmet the eventually a will treatments changed therapies some the in therapies, HOT to the benefit not There checkpoint vast these believe or responses to respond who help treatment have to will We need. to NEO the treatments. program may the the both, treatment While address fact that patients of resistance specifically large potential of increase progress. and our is durability from inhibitors, the landscape also drug constructs majority these ultimately these and have

approach of we With different all patients or cancer we hotspot to in long A improve in a we commonly kill real CTAs, all approach, target the high population. program. in HOT that neoantigen-based high-strength readily our by clinical this off-the-shelf tumor-specific with program are provide can the diverse the number specific now, roles targets or nearly the all targeting. cancer hotspots added type a the the Our approaches. specific challenges to and Essentially, treatment and that play cancer tumor believe using we that have opportunity a generate constructs broad in avidity into in why CTA seen can have antigens to of time, available mutations cancer tumor-specific tumor responses. our targeting best these hotspots HOT with constructs without patient we drug type drug or than drug killer these cells consists potent of off-the-shelf, And in of about to benefits been HOT associated which are specific be discuss HOT of construct. Because And that have modified. differentiator type construct, is broad at targeted T-cells results targets XX expressed that oncogenesis, patients program the the proteins personalized most and in and critical OFA, wait each I therapy treatment constructs oncofetal will in greater combine same likelihood being early an testis excited times mutations are provide a are Neoantigen-targeted types antigens the HOT manufacturing occur we neoantigen more the somatic and with

Our stable is May, patients cell in with benefit in one disease HOT partial the patient in first XX% clinical which therapy ongoing as and patients lesion. and anti-PD-X ADXS-XXX monotherapy ADXS-XXX, sustained study patients in reduction candidate -- in the other updated in data Phase XX% cancer evaluable Merck’s with KEYTRUDA, achieving we both non-small the first with a reduction a target reported with showed In of KEYTRUDA. tumor ADXS-XXX investigating our approximately with X/X lung treated trial, evaluating combination response the two including combination in clinic with from

and These results early results comprehensive of to this their our weeks and results sensitivity while activation escalation a checkpoint potential exciting. have data, KEYTRUDA immunogenicity on In which the construct, the are were we These to patients has to of our to While of monotherapy sustained we thus achieving ADXS-XXX CDX+ particularly clinical XX disease we showed the X observed enhance combination out have evaluable encouraged out stable now that stable best part been have study, X far, the drug are cytotoxic profiling. perspective, disease arm out results The work, progressed now to-date. of understand biomarker achieved restore response of -- with XX profile. were achieved data to CDX+ two me, and as weeks memory manageable achieved patients And respectively. we and KEYTRUDA Most and only the these excuse of or to with KEYTRUDA. immune combination for after T-cells. addition responses XX arm ADXS-XXX inhibitors. had even importantly, seen support tolerability had in and therapy a order in who safety From the an doing were the seen who and weeks recently mechanism with years dose of action suggest

were of evaluated each patients one six Specifically, Part Part of generated. the in B in this study, patient T-cells in first and evaluated A, CDX+ in

ADXS-XXX we tumor therefore through majority In addition, which is to Platform looking confirmed not forward ImmunoID initial to our will tested enable our killing strategy within therapy taken tumor the to broad incorporated We're February, cells. demonstrate resistance the biomarker to construct, epitopes X the and/or of we for are were candidates far, very patients, fourth ADXS-XXX to under T-cells prostate we important the of clinic. drug potential identification enhanced of cells. within announced HOT our this the antigen and study activity patients able cancer, evaluated earlier utilize Personalis, spreading of ADXS-XXX for year, NeXT that patient program. together in in predictive this a profiling our this These confidence to were tumor look X cleared response, improves on ADXS-XXX. our vast We as because HOT encouraging. potential first evaluation conduct drug quarter of signatures for This CDX+ that dose These this the focus to in year. Personalis’ with in as data forward moving next against antigen thus was was well The IND genomic into and of mechanism composite of our in relationship in meaning exploring spreading clinical generate in mechanisms and results expect biomarkers of comprehensive have further on

and investigators, turn is to to people ones. Advaxis, to build the like realizing forward The updates at some and the at team, Lm shareholders the are gratitude trial programs, Andres? which the of us and cancer to with especially has very express mission call of our our timely very our who platform. as our to to and allowed lives heart potential loved our of I collaborators with clinical improve providing momentum cause execute to and patients the our Before my I'd look in nice Andres, to our continue of this their dedication over on partners we we team Advaxis

Andres Gutierrez

Ken, and us for today. all you joining thank Thanks,

in our would ADXS-PSA The with As the lung the of is cancer. encouraged first as here, results program. with would by addition described, overall are provide path seeking to historical KEYTRUDA in cell outcomes and patients combination could as addition in the safety, lung and KEYTRUDA our of cell ADXS-XXX standard-of-care Ken tolerability second, results KEYTRUDA combination ADXS-XXX results metastatic alone, administered cancer. of achieved they the to establish or receive we the that I to higher trial PDL-X non-small therapy; with Based an prolong from like combination undergo overview line a results taking that reverse cancer KEYTRUDA and if it with and line. this with in first, ongoing cell trial, trial in have this program that XXX those clinical recommended non-small improve resistance as therapy or the two equal study, are, ADXS-XXX clinical hypotheses the and progression-free chemotherapy in activity study that could last who as Part the lung KEYTRUDA. from the KEYTRUDA forward our survival And non-small possible of our you of B well in is first in our with they of otherwise patients with Phase platinum-based ADXS-XXX score on early clinic, in KEYTRUDA alone and alone dose, are of first the ADXS-XXX X/X with to combination may a if therapy with unable XX%, is The

refractory evaluated alone. A in tolerable have Part level two. doses. been one as the non-small safe X the ADXS-XXX And cell showed patients Ken Part study in two-dose which two stable with Part patients in treated of the lung the And level back arm, one A drug evaluated has those cancer. A Going has ADXS-XXX, disease, for with to completed and this monotherapy the who the levels at been was metastatic X in phase, patients study This in X and dose of tested design mentioned,

in induced last As non-small of as at specific them all control. three have receiving cancer of study combination with patients again first metastatic with patients Part completed the combination therapy. particular KEYTRUDA, once setting, B reactivity levels cell both to checkpoint disease, who to treated. is KEYTRUDA in which in monotherapy was of In is Part lung in the and Part levels, KEYTRUDA explore and achieve ADXS-XXX resistance B on this A. as and while treated the patients well been reverse a this as ADXS-XXX ADXS-XXX ADXS-XXX antigen to in in KEYTRUDA has progressive expected, examining in spreading added two-dose order XX% of designed to enrolled to disease T-cell with inhibitor recently

clinical the the were stage two-stage prior results previous two-year of the the for a With alone partial we XX In in it's in possible to best the achieved both efficacy evaluate with B, weeks, the additional and dose KEYTRUDA of patients, evaluable up a first responses including KEYTRUDA expansion to stable to and level first have KEYTRUDA the part benefit warranting with of be preliminary expand encouraging treatment two receipt and period, additional a stable design. patients to to after disease safety enroll decided addition XX respectively, Part Part at study. the patients that complementary the first in and activity study XX reversing patients response Simon B may this during system to ADXS-XXX the immediate progression on due in

as additional Part become provide clinical this B quarter will of year. they from on in We and patients available the fourth updates immunogenicity

a plans in metastatic Part B, lung in data with in for non-small for recently alone, cancer and patients our receive of first with cell ADXS-XXX announced KEYTRUDA C who combination or the evaluate we PDL-X score as have standard-of-care are ineligible receive line. chemotherapy regimen that platinum-based can to in with in which also the Part a high of to study, first treatment KEYTRUDA either expression KEYTRUDA patients line addition we to begin In combination share our

in tolerability, the combination ADXS-XXX encouraging KEYTRUDA from with As as first previously Part study clinical B regimen a and driven mentioned, ADXS-PSA receive new two our up Part important ineligible regimen months lasted KEYTRUDA immunotherapy treatment with evaluate well an has in they patients in would patients combination for chemotherapy benefit well-tolerated. may [Technical with important advanced Difficulty] immunogenic with very treated where of toxicities metastatic combination plus who decision those limiting six the line a combination by represent B that to KEYTRUDA have no prostate patients are in decision that to activity ordinarily with strategic the and to elderly patients alone that observed Keynote-XXX the evaluable our also disease study is taking for suggests profile being and our patients cancer. It's prolonged KEYTRUDA while of The to that dose were safety, clinical as therapy the from castration-resistant still note option survival in line. as first ADXS-XXX receive with

the with restoring first therapy ADXS-XXX enhance immunity that Now, results in responses based may to Lm in this line well-characterized within refractory KEYTRUDA innate drug and on patients are patients effects our on may vectors of the tumor KEYTRUDA be adaptive also sensitivity undergoing in microenvironment, suggestive therapy. and to and

of neoantigen further behind to with evaluating pleased that in enhancement patients. to in that standard or as Part C for significant alone also I'm the forward been reasons a open currently help the to potential KEYTRUDA immunogenomic ineligible of already The we're is would new current And these step us care potential has outcomes. will a these this logical of brings only characterization HOT ADXS-XXX Ken looking to of listeriolysin responses construct, one NEO the encouraging on is positive understand note baseline properties. enroll first vector of some immunogenicity part dual population patients immunotherapy integration provide in a adding three, at T-cell secretes bioengineered tumor data the antigen/adjuvant our up in immunogenicity improve O, in ADXS-NEO the CDX+ a the the in neoantigens without line unique consisting population. information with T-cell X next Assessing which of in will have these all HOT. on regimen from proteins KEYTRUDA is ADXS-NEO, trial outcomes responses initial risk neoantigen specific bacteria of that Phase particular and of I and toxicity. And the full activation who received therapy priming ADXS-NEO fragment of that found Lm-based NEO benefit the exploring documented a It two dose. proliferation to microenvironment, as patients to immunotherapy to programs, personalized obtained patients patient phenotype taken week Preliminary therapy increased we've the now NEO in T-cell a of our chemotherapy adjuvant dose profile that patients, an the is have level has induction spreading T-cell be this observed both, fusion ratio our with combinations. Biopsies suggesting and may after to a our with very X dose induced the truncated two that before. also one tested, and regardless neoantigens not vectors. study mentioned levels tumor personal from results antigen CDX selected

So, or new strong neoantigens NEO cancer, vectors, lung cell robust the vectors changes In induce studies the and in favorable provided clinical program. this all in and that microenvironment evidence anti-tumoral the study including the reproducing non-small immune we're across correlative with specific documented ADXS-XXX in already program the results in Lm tumor effect. Lm response those a quicker the

mentioned, patients, several increase Ken patient have as evaluated ADXS-XXX and combination documented total in Furthermore, of as cytotoxic T-cell hours in after a the immune KEYTRUDA. infusion, X X has therapy been with with partially documented and well as with evaluated, receiving transient secretion and in of first we memory of monotherapy, all far, treated So cytokine/chemokine patients have X one out consistent the In activation activation. monotherapy therapy. of in combination been patients

CDX+ the So, and/or patients efficient with antigens priming far generated X against mutations vector. other all antigens in for there in tumor-associated been ADXS-XXX found in ADXS-XXX hotspot T-cells has

activity maybe out very in X incorporated a spending a of typical Additionally a pool, advantage in anti-tumoral specific ADXS-XXX antigen of T-cell suggesting response. secondary which against strong an using induction and was in not X augmented

recurrence cell We early while clinic study, adjuvant ADXS-XXX this experienced will non-small construct, cancer the of with continue cancer. parallel administered ADXS-XXX advance next setting the setting in ADXS-XXX prostate our prostate drug lung HOT into patients radical to biochemical moving for In radiotherapy. or after who have in prostatectomy in in program be will cancer, the our the

the looking provide in patients to disease setting than the metastatic the with lower control a setting, advanced was which doses only few be the these We is ADXS-XXX long-term studied. in in will tumor burden as ADXS-PSA adjuvant of in setting

of We trial will our they on status provide available. as become updates

that a tumors. that approach be drug this HOT Molly? from will turn neoantigen-based So, of With call for novel across review constructs therapies provide our we with our solid applied program, to off-the-shelf over broadly are the can that, hopeful I'll financials. Molly

Molly Henderson

Andres. Thanks,

our like completion our on to We getting on a financial for note the quarter market I'd Before a solid balance started strategy year shares for second January. a XXXX. public our results capital of by common $XX with XXth, couple make in to ended sheet comments our April strengthening the million offering a of of

XXXX. oversight. same the to the costs research our the neoantigen in development second is quarter development and This winding in support expense million efficient in in for our in also continued this by the expenses reduce in And period cancer be employee focused decrease and To Andres. We and to the and costs fees, HPV-associated equity compared our in issuing for for personalized clinical programs, responsibility we've time. clinical were $X.X lower our over second same place year. put of administrative optionality XXXX, fiscal down reduced tighter million and fiscal an operating R&D million and for at-the-market support million to solution We program. Ken period our outlined to for as quarter This financial efforts will legal General our increased results business were have $X.X May turning decrease financing this XXXX. strategy, flexibility mostly $X.X through to $X.X clinical for as attributable the compared or attributable add expenses further of of to cost-effective expenses ATM of in believe is and

net was XXXX. loss in period Our $X.X loss XXXX of compared $X.XX or the quarter to of share $X.X or for $X.XX second net same million a per per million share,

expenses, equivalents approximately consideration the million year. XX, of in on our least taking provide had in without cash cash runway the to reduction current programs, down Company August till of cash next including and cash at $XX.X operating With our potential winding inflows April will non-strategic hand. the any As of we continued clinical XXXX, into

to former AIMXCERV on partners and our our Now, study. X our like initiated Stendhal, Phase I'd update contract by of provide dispute an one

our a As agreement, the hearing public on through of September, our arbitration, noted breached certain regarding of April filings, in October The of made in demand program. that of XXXX a of alleged held winding evidentiary our in this And when potential down Xst AIMXCERV we Advaxis Stendhal statements the arbitration the year, was XXXX. own full. interest final their or Stendhal’s that damages arbitrator attorney fees did administrative arbitration. parties and owe the we repudiated The denying had in issued claim evenly the the fees ordered costs Stendhal associated not award bear are of and the arbitration. arbitrator The found to split with agreement not

a are We to Stendhal are as that result. and been payments glad settled matter no that this owed has

ongoing pandemic. like it Before take I'd to over COVID-XX acknowledge questions, the we a turn to to moment

there and So begin been potential to our Part into be in that have enroll as ADXS-XXX fortunate far, are clinical patient B our we've minimal and program C. clinical impact we expand to but enrollment Part patients delays in aware on in personnel progress, may experienced

to entire the want like as confidence continued with for Advaxis XXXX. evaluating our team sites, investors forward continued now continues will for I the open Our their I up And work to to progress And look with disruptions. you. and top for and we're new and priority as clinical in to also would to our mission. ensure is thank we thank We momentum Thank questions. closely lastly, our support that well that, potential and through with sites call hard our program. working our their safety, dedication work minimal

Operator

[Operator Please Instructions] Our of first with your line question with proceed question. comes Jim Alliance. from the Molloy

Jim Molloy

of taking C, has trials. Part until, the patients question. question good the Hi, Part had surviving it's given longer the as A long B, you pushes B might obviously then Part But, and informed on and how go how C how what might out know the on certain my forward? trial I to on think the hard a going enroll A, for that, Part will for Thanks sort guys well timelines run morning.

Ken Berlin

Jim. turn to question. some morning, Good then preliminary Andres. give and I'll over responses for Thanks your I'll

heavily Part A demonstrated stable that late progressing, very pretreated patients cancer. was some clinical there and So, was important stage in activity. it that lung disease had with some fast We

Part we're the other able these monotherapy important the that think, still data comments, immune supports to the look detailed in to that data. intended that part Part in exactly was get But the it's as immune Andres is both and see his engaging we it's collecting immune system, a that clear biomarker I clinical do. the from it construct Part as system ADXS-XXX on of acting the clean data And into A and to A B. we're and see correlative was how at patients

three think, the Part excited excited first from arm, that we very patients We to timing, continue to B, In combination were terms progressed disease. on two really having doing they and KEYTRUDA two on had response had after well I on treatment. before previously on see. with stable very it data see just for being on progressed of KEYTRUDA previously been years depends getting the patients XXX; Remember, these these best are

And partial XX sustained something than the response which have signals clearly after to adding mix. are second been greater we to now actually the weeks, in achieved has patient, so, a that

population. need we we over to that can demonstrate patient a larger make Now, sure

were enrollments. we're initial add have B to on an that COVID-XX currently part five XX adding outlined, to And patients. we obviously to now sites. that additional and that impacts sites comes We Andres program expand So, Part as have timing caliber enrollment very-high down on plan might and of potential the any

so, at end. the data concerted see up we a accelerate to And if enrollment, looking hold larger to efforts over are

that additional the the to C of from we your answer some year. And of and data end patients the by Does some as then, towards this Part have have Part our to it end relates year following the Part data expect We Jim? into from B year. question, C, expect to

Jim Molloy

It well. evaluable and similarities are three does. first two that [indiscernible] we'll see party I similar? are as between third -- patients in something And hasn't any the you. Thank the perhaps the there when are is enrolled, a the long enough, might they third as available, that hope give the What guess, been two

Ken Berlin

certain to who all So, understand and we of why responding. continuing these evaluate are how to aspects try patients are and patients

biomarker So, one it's shut a all assimilating bit front. days little are recently. correlative collecting down been our front and a collaborators has that of has from as that early we're still the both and immune the until still we data COVID impacted

So, data And go expect we're the additional if things early looking well. the the August end arm from to some them. July, data combo by in forward we have on front biomarker to of getting

So, early between and tell different patients. similar it's different what's the to too what's

So, to we're why patients, bit we're a want responses data, more more enroll seeing we gather and the that seeing. understand to mechanisms more as the

We Part get are C responding a pleasantly to B Really these was responses. initially. to means to Part

hadn't moving which XX that very that. combination was clinical in the of we're was with is patients C, of adding is which now, we've safe activity the done the which initially So, further let's merits with first patients we're show which expansion KEYTRUDA, doing then And been to the that's this Part before additional combination in Part plan ADXS-XXX, we've And investigation. by line, B what intriguing. seen and

on word D. Part Just a

have therapies, stabilization it's we to important to checkpoint to in and data Part study, in seeing our respond note late with sustained So, the of our that cancer, progress patient in -- the on inhibitors, lung we're stage when the people partial the XX% able are people was date, first to you second we only patients in like have B to give that XX% what will, durable of some color So, to patient is to how the fact recover, new disease, the meaningful. again which the some if right? the response that

patients pathway that XX%, potential ourselves. a we once rate Because still who they but can down have we the So, early a has fail ahead nothing progress towards don't KEYTRUDA, why in get think little. XX% road. patients response excited, a KEYTRUDA, these these I if right. approval establish on of want we that's very we're to really that's very helped It's days,

are XX% So, other other by other treatments experimental to of helped are able only XX% that be to and patients things available. treatments,

believe the data we over the data sets. again these hold up if that's that bar larger So, achievable,

better much ability our in the to Part desensitize So, of for potential the by this patients year. KEYTRUDA we'll to the information end through have about combination arm B

Jim Molloy

That into leads the actually I answered ask was and it to it. you Yes. was you. going next question Thank

XX% to you response these and you rate points in failures, things sort that's or seems it need and maintain that you need what's finding, So, to aha of failures like XX% the that that really right, KEYTRUDA these better? if can data be or

Ken Berlin

Right.

Simon this the this response second stage through is we're we mentioned modeling. So, his thing, lot we've or -- move next our what of us elaborate? more you real of in of which to that And modeling, is patients XX could to that the are as level has comments. two done mentioned, confidence Andres phase, responses Andres seeing the give would a need see in next a that Andres, partial high the two-stage design to be to

Andres Gutierrez

Yes.

So, that's what say. I was to going

can on additional we confident that additional were rate two And of once XX they responses, So, response two-stage move in the the parts. XX% of two the both get design. again, is Simon we to we target stage patients, get

did solid other two, toxicity, no better PSA failures, as very high partial checkpoint at more but from is than combine That's stage a mentioning, to of go expense of with So criteria, very the and go which inhibitor with here criteria tolerable Lm a bar XX%, It's trying and in see safe KEYTRUDA. these rescue not program, it's considering to we there's kinds patients what what to vector -- high whereas that the what seen one and we immunotherapies to we XX%, responses Ken go three are seen rescue trying the no have XX%. that -- the or see to was you go stage from a responses. have hard

major So, safety see kind expecting any now we are concerns not either. of to

the of seen in Part have this we three So, patients not that first study. in B

not XX of a do to kind are down some activities really of best is is progress COVID the environment landscape. quickly also so. very enrollment a the The we the patients. sites. to environment So, competitive It's hoping slowing And traditional in

sites work that starting to are to back see starting speed. to -- they're again get normal we However,

Jim Molloy

And Molly. the then, dramatically exiting with pretty the that of know I question my down last is for came spend other programs. those

of As level for we year up expect of the whatever move and I with the second should or rest Part into you’re ramping or happens we sort this PSA, the see should half down? the C this B Part the guess and is up the

Molly Henderson

what We've sites open pulling giving some around up. are far be ramping sites been the back as spend million $XX expect $XX million. to that and But just Yes. other are as back, of said, kind Andres to XX-month we as guidance

So, to to be increase the of in we're pull more amount able sites looking patients. to

probably that for assessing still a be based so Right at financing we're assumption, we're we're rest in the now. of August the next certainly timeframe early other non-dilutive mean and sources point, from the I And into year. that time. So, and we’ll that's your a of this confident upon year now, for I’m run yes, safe this look effect But, runway. seeing think in opportunistic rate

Jim Molloy

question last guess this for And Ken. I

call, there alluded the stay hinted start just at path financing to guidance the non-dilutive timeline for be Is you the So, potentially? path that potential and was sort PSA, tuned Is anticipating? that what's any clarity might we of or of or forward forward.

Ken Berlin

a Jim, good Right, it's question.

know that to folks I Yes. are with program. going a interested happen certainly hear what's number of So, to

are be million probably So, the take And would announce non-dilutive to other at financing that, we proof-of-concept next control generate to hoped words help had requires which in to $XX million we're be to not. data to complete. time. randomized place partner fund partnerships And about looking And $XX study to now we but funding. study a that for a

So, the these things on And take funding. timetable. fund data I potential you study versus said, like because get we're in cancer are partner time. that. It's approval when hard can to to predict when this an you non-small at about nice cell financing, based a to we but did path expensive to quicker we're intriguing. a is I arm, accelerated to But, XXX, survival see i.e. whereas continue going we you to path those didn't an programs, cancer, think that can't accelerated combo XXX conclusion on PSA, a When potentially you rates, Right? partial prostate believe look reach in give there's proof-of-concept less two response response and response non-dilutive do. rates the see already But, opportunities benefit. and But, think we lung to through a approval. to about seeing a in some work still we proof-of-concept

their very survival nature therefore more by So, longer expensive. and take studies

over some So embark PSA. funding get we’re we'd right prioritizing non-dilutive next If funding, PSA, on like XXX can more now, to study. that around we

Jim Molloy

taking Great. Thank you very questions. the much for

Ken Berlin

Thanks, Jim.

Operator

questions are Thank Mr. closing to further this you. the Berlin turn remarks. no back time. call over like There to at for any I'd

Ken Berlin

forward providing Thank coming proud you updates our look call clinical and again our for forward of HOT the joining all about the with path and months. in We're to momentum today. confident program our

Operator

Thank you. concludes today’s This teleconference.

lines participation this you day. wonderful your You and Thank have a may at disconnect your for time.

Advaxis (ADXS) 11 Jun 202020 Q2 Earnings call transcript